References
- Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.
- Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989–2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113(9):2457–2463.
- Massagué J. TGFbeta in cancer. Cell. 2008;134(2):215–230.
- Assoian RK, Komoriya A, Meyers CA, et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258(11):7155–7160.
- Macias MJ, Martin-Malpartida P, Massagué J. Structural determinants of Smad function in TGF-β signaling. Trends Biochem Sci. 2015;40(6):296–308.
- Tang J, Gifford CC, Samarakoon R, et al. Deregulation of negative controls on TGF-β21 signaling in tumor progression. Cancers (Basel). 2018;10(6):1–13.
- Lin X, Chen Y, Meng A, et al. Termination of TGFβ superfamily signaling through SMAD dephosphorylation – A functional genomic view. J Genet Genomics. 2007;34(1):1–9.
- Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125(5):915–928.
- Care NRCCftUotGft, Animals UoL. Guide for the care and use of laboratory animals. Publication No 85–23(Rev). 2011;327(3):963–965.
- Dagher J, Delahunt B, Rioux-Leclercq N, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017;71(6):918–925.
- Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
- Huang X, Wang L, Chen Y, et al. Poor prognosis associated with high levels of thymidine phosphorylase and thrombocytosis in patients with renal cell carcinoma. Urol Int. 2017;98(2):162–168.
- Therneau TM. A package for survival analysis in S. 2015. R package version. 2017. 2:280.
- Harada M, Morikawa M, Ozawa T, et al. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. Cancer Sci. 2019;110(1):209–220.
- Samarakoon R, Dobberfuhl AD, Cooley C, et al. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species. Cell Signal. 2013;25(11):2198–2209.
- Samarakoon R, Helo S, Dobberfuhl AD, et al. Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses. J Pathol. 2015;236(4):421–432.
- Besser D. Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3. J Biol Chem. 2004;279(43):45076–45084.
- Igawa T. Role of protein phosphatases in genitourinary cancers. Int J Urol. 2017;24(1):16–24.
- Samarakoon R, Rehfuss A, Khakoo NS, et al. Loss of expression of protein phosphatase magnesium-dependent 1A during kidney injury promotes fibrotic maladaptive repair. FASEB J. 2016;30(10):3308–3320.
- Hager M, Haufe H, Lusuardi L, et al. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest. 2011;29(7):427–438.
- Geng J, Fan J, Ouyang Q, et al. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget. 2014;5(14):5700–5711.
- Zhang Y, Tao R, Wu S-S, et al. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A. J Exp Clin Cancer Res. 2018;37(1):116.
- Lu J, Zhong Y, Chen J, et al. Radiation enhances the epithelial- mesenchymal transition of A549 Cells via miR3591-5p/USP33/PPM1A. Cell Physiol Biochem. 2018;50(2):721–733.
- Seoane J, Gomis RR. TGF-β family signaling in tumor suppression and cancer progression. Cold Spring Harb Perspect Biol. 2017;9(12):a022277.
- Chen J, Xia Y, Lin X, et al. Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis. Lab Invest. 2014;94(5):545–556.
- Lu X, An H, Jin R, et al. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene. 2014;33(22):2918–2927.
- Stebbing J, Lit LC, Zhang H, et al. The regulatory roles of phosphatases in cancer. Oncogene. 2014;33(8):939–953.
- Rehfuss A, Higgins P, Samarakoon R. MP24-13 evaluation of protein phosphatase PPM1A as a novel target in renal fibrosis. J Urol. 2016;195(4S):e274–e275.